What is the level of liabilities of Oryzon Genomics this year?
Oryzon Genomics has a debt balance of 25.13 M EUR this year.
In 2024, Oryzon Genomics's total liabilities amounted to 25.13 M EUR, a -19.28% difference from the 31.13 M EUR total liabilities in the previous year.
Oryzon Genomics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Oryzon Genomics's financial stability, operational efficiency, and long-term viability.
By comparing Oryzon Genomics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Oryzon Genomics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in Oryzon Genomics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Oryzon Genomics has a debt balance of 25.13 M EUR this year.
The liabilities of Oryzon Genomics have increased by -19.28% dropped compared to the previous year.
High liabilities can pose a risk for investors of Oryzon Genomics, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that Oryzon Genomics has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of Oryzon Genomics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of Oryzon Genomics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of Oryzon Genomics include investments, acquisitions, operating costs, and sales development.
The liabilities of Oryzon Genomics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, Oryzon Genomics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, Oryzon Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oryzon Genomics is expected to pay a dividend of 0 EUR.
The current dividend yield of Oryzon Genomics is .
Oryzon Genomics pays a quarterly dividend. This is distributed in the months of .
Oryzon Genomics paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
Oryzon Genomics is assigned to the 'Health' sector.
To receive the latest dividend of Oryzon Genomics from 8/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.
The last dividend was paid out on 8/26/2024.
In the year 2023, Oryzon Genomics distributed 0 EUR as dividends.
The dividends of Oryzon Genomics are distributed in EUR.
Our stock analysis for Oryzon Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oryzon Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.